AQST · Aquestive Therapeutics, Inc.

Track AQST — free

$4.65 +0.10 (+2.20%)

Russell 2000 member Rebalance outlook locked

Market Cap

$584.88M

125.51M

Volume · Oct 5 1.09M Avg daily vol (3M) 2.66M

Up next

Next earnings call

Nov 8, 2026 Est · unconfirmed · in 5 wks

Latest filing: 10-Q

filed Aug 11, 2026

Q1 2026 earnings call transcript

call held May 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$54.09M

Trailing 12 months

Net income (TTM)

−$78.23M

Trailing 12 months

Revenue growth YoY

+38.1%

Year over year

Operating margin

-97.5%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-7.9%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$43.46M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+25.8%

Year over year · more shares

Price change (1Y)

-21.1%

Trailing year

Short interest

21.6%

Latest settlement · 11.8 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +5%

above

Price vs 50-day avg −0%

below

RSI (14) 44

neutral

MACD trend Negative

52-week position 35%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −15%

trailing

6-month return +9%

trailing

YTD return −30%

this year

Relative strength −4%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $5 › 200d $4 — 50d above 200d

Institutional flow Accumulating

+3% holders QoQ · +25 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

21.64% of float · ▲ +6.6% MoM · 11.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

186 holders — near 3-yr high, broad support

Squeeze score 84

high risk · 0–100

Fundamentals

Weak

Revenue growth +1%

Y/Y

EPS growth −53%

Y/Y

Free cash flow $-53.0M

Balance sheet $83.7M

net cash

Quant / Vol

risk profile

Very High

Volatility 77%

annualized · 1-yr

Max drawdown −61%

past year

ATR 5.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 4 of last 4

Latest guidance · from the 8-K filed Aug 11, 2026

Total revenues · 2026 Outlook $46M – $50M

prior FY $44.55M midpoint +7.8% Y/Y

Guided vs delivered · last 4 settled

Total revenue full-year 2024

guided $57M – $60M

guided $57M – $60M $57.56M In line

Total revenue full year 2023

guided $47M – $50M

guided $47M – $50M $50.58M Beat +4.3%

Total revenues full-year 2021

guided $47M – $49M

guided $47M – $49M $50.83M Beat +5.9%

Revenue guidance for 2020 full year 2020

guided $42M – $46M

guided $42M – $46M $45.85M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 5 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+5% Bullish

Price vs 50-day avg

−0% Neutral

RSI (14)

44 Neutral

MACD trend

Negative Bearish

52-week position

35% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $5 › 200d $4 — 50d above 200d

Institutional flow Accumulating

+3% holders QoQ · +25 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

21.64% of float · ▲ +6.6% MoM · 11.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

186 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $3 Now $5 · 35% Range high $7

vs 200-day avg +5% vs 50-day avg 0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Cash and cash equivalents	98.5M	Q2 2026	—
Doses manufactured	48M	second quarter 2026	—
Gross Margin on total revenue	74%	Six Months Ended June 30, 2026	—
Non-GAAP adjusted costs and expenses non-GAAP	35.23M	Six Months Ended June 30, 2026	—
Non-GAAP adjusted EBITDA non-GAAP	-6.97M	Six Months Ended June 30, 2026	—
Non-GAAP adjusted EBITDA excluding Non-GAAP adjusted R&D expenses non-GAAP	624K	Six Months Ended June 30, 2026	—
Non-GAAP adjusted EBITDA loss non-GAAP	$5.2M	second quarter 2026	—
Non-GAAP adjusted manufacture and supply expenses non-GAAP	7.16M	Six Months Ended June 30, 2026	—
Non-GAAP adjusted R&D expenses non-GAAP	-7.59M	Six Months Ended June 30, 2026	—
Non-GAAP Gross Margin on total revenue non-GAAP	75%	Six Months Ended June 30, 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
AQST Aquestive Therapeutics, Inc. this stock	$584.88M	-29.6%	+0.8%	—	21.6%
TAK Takeda Pharmaceutical Co Ltd	$60.23B	+14.6%	—	—	0.1%
GALDY Galderma Group AG/ADR	$46.00B	-6.5%	—	—	0.0%
TEVA Teva Pharmaceutical Industries Ltd	$45.67B	+26.7%	+4.3%	64.3	2.7%
HLN Haleon plc	$40.72B	-13.0%	—	—	0.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

186

% held: 58.8%
Net QoQ: +72.6K sh
Top holder: Bratton Capital Managemen…

Held Float

View

Held by Funds

Fund positions

113

View

Short & Settlement

Short Interest Rising

Shares short

27.2M

Days to cover: 11.8d
Change: +1.7M sh

View

Short Volume

Short vol %

45%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

11.7K

Value: $55.8K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

46.0%

Week of: Aug 31, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$44.5M

Net income (FY): $-83.8M
EPS diluted: $-0.78

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 29, 2026
This year: 17

View

Proposed Sales

Value

$244.0K

Shares: 50.0K
Filed: Sep 15, 2026

View

Earnings & Events

Webcasts

Last webcast

Aug 12, 2026

View

Performance

	5D	20D	120D	MTD	YTD
AQST	-2.8%	-15.0%	+8.6%	-1.7%	-29.6%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	-2.6%	-14.5%	-3.6%	-2.7%	-42.4%

Key facts CIK 1398733 CUSIP 03843E104 13F (30d) 2 filings 2 filers Visit website Investor relations

AQST · Aquestive Therapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance